"CARD's goal is to further stimulate and accelerate Alzheimer's and related dementias research through its data-driven and collaborative approach that emphasizes robust, replicable findings and cooperative progress," said Dr. Andrew Singleton, director of CARD. "CARD scientists engage and collaborate with researchers in government, academia, and industry to create research resources and expand upon expertise to add broad value to the field. We work across scientific domains and disease boundaries to bridge basic, preclinical, and clinical research and accelerate translational research on these diseases."
Together, Invicro, DTi, and CARD aim to improve clinicians' ability to assign risk to patient populations as well as monitor and treat those patients and support early clinical trial enrollments. This effort could greatly enhance the assessment of the efficacy of potential therapies for neurodegenerative disorders as measured through changes in imaging and cognition. A greater understanding of these relationships better defines the spectrum of neurodegenerative diseases and their progression in individuals and patient groups.
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
"Invicro is delighted to be collaborating with the internationally renowned team of scientists at CARD to advance precision medicine initiatives for dementia and other neurodegenerative diseases. This will further strengthen our commitment to support intervention, prevention, and treatment in these debilitating diseases," stated Dr. Roger Gunn, Chief Scientific Officer, Neuroscience for Invicro, and Professor of Molecular NeuroImaging at Imperial College London.
About Invicro
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro's multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, and systemic and rare diseases. Invicro's quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro's industry-leading software informatics platforms, VivoQuant® and iPACS®, as well as their pioneering IQ-Analytics Platform, which includes AmyloidIQ, TauIQ and DaTIQ.
